
Brenda Libby Coleman
Examiner (ID: 13884, Phone: (571)272-0665 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1202, 2611, 1624, 1611 |
| Total Applications | 3154 |
| Issued Applications | 1967 |
| Pending Applications | 488 |
| Abandoned Applications | 741 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19248659
[patent_doc_number] => 20240199646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => REDOX ACTIVE MATERIALS, PROCESSES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/391693
[patent_app_country] => US
[patent_app_date] => 2023-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18391693
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/391693 | Redox active materials, processes and uses thereof | Dec 20, 2023 | Issued |
Array
(
[id] => 19331276
[patent_doc_number] => 20240245706
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/544956
[patent_app_country] => US
[patent_app_date] => 2023-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26319
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18544956
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/544956 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | Dec 18, 2023 | Issued |
Array
(
[id] => 19142088
[patent_doc_number] => 20240140911
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3, 4-TETRAHYDROCYCLO-PENTA [B]INDOL-3-YL)ACETIC ACID(COMPOUND1) FOR USE IN SIPI RECEPTOR-ASSOCIATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/542913
[patent_app_country] => US
[patent_app_date] => 2023-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 213
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18542913
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/542913 | Crystalline l-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in SIPI receptor-associated disorders | Dec 17, 2023 | Issued |
Array
(
[id] => 19354036
[patent_doc_number] => 12054465
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-06
[patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/533894
[patent_app_country] => US
[patent_app_date] => 2023-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 26382
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18533894
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/533894 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Dec 7, 2023 | Issued |
Array
(
[id] => 19448889
[patent_doc_number] => 20240309019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/530405
[patent_app_country] => US
[patent_app_date] => 2023-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 127771
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 494
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18530405
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/530405 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | Dec 5, 2023 | Pending |
Array
(
[id] => 19389317
[patent_doc_number] => 20240279187
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => COMPOUNDS, DEVICES, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/529334
[patent_app_country] => US
[patent_app_date] => 2023-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72579
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18529334
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/529334 | COMPOUNDS, DEVICES, AND USES THEREOF | Dec 4, 2023 | Pending |
Array
(
[id] => 20256061
[patent_doc_number] => 12428404
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Inhibitors of LRRK2 kinase
[patent_app_type] => utility
[patent_app_number] => 18/514959
[patent_app_country] => US
[patent_app_date] => 2023-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36170
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 125
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18514959
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/514959 | Inhibitors of LRRK2 kinase | Nov 19, 2023 | Issued |
Array
(
[id] => 20106941
[patent_doc_number] => 12357639
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-15
[patent_title] => Heterocyclic compounds as pad inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/513229
[patent_app_country] => US
[patent_app_date] => 2023-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57055
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 205
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18513229
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/513229 | Heterocyclic compounds as pad inhibitors | Nov 16, 2023 | Issued |
Array
(
[id] => 19938851
[patent_doc_number] => 12310964
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => Compositions and methods for the treatment of Lowe Syndrome
[patent_app_type] => utility
[patent_app_number] => 18/389574
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 31
[patent_no_of_words] => 5706
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18389574
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/389574 | Compositions and methods for the treatment of Lowe Syndrome | Nov 13, 2023 | Issued |
Array
(
[id] => 19543047
[patent_doc_number] => 20240360083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => THERAPEUTIC COMPOUNDS AND COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/507013
[patent_app_country] => US
[patent_app_date] => 2023-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60622
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18507013
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/507013 | Therapeutic compounds and compositions | Nov 9, 2023 | Issued |
Array
(
[id] => 19050825
[patent_doc_number] => 20240092794
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => NOVEL PRMT5 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/502780
[patent_app_country] => US
[patent_app_date] => 2023-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 313
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502780
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/502780 | NOVEL PRMT5 INHIBITORS | Nov 5, 2023 | Pending |
Array
(
[id] => 19027231
[patent_doc_number] => 11926578
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-03-12
[patent_title] => 8-(4-nitroxybenzylideneamino)naphthalene-1,3-disulfonic acid as an antioxidant compound
[patent_app_type] => utility
[patent_app_number] => 18/385586
[patent_app_country] => US
[patent_app_date] => 2023-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3626
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385586
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/385586 | 8-(4-nitroxybenzylideneamino)naphthalene-1,3-disulfonic acid as an antioxidant compound | Oct 30, 2023 | Issued |
Array
(
[id] => 19151135
[patent_doc_number] => 11976031
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-05-07
[patent_title] => 8-((4-hydroxy-3-methylphenyl)diazenyl)naphthalene-1,3-disulfonic acid as an antioxidant compound
[patent_app_type] => utility
[patent_app_number] => 18/385808
[patent_app_country] => US
[patent_app_date] => 2023-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3823
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385808
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/385808 | 8-((4-hydroxy-3-methylphenyl)diazenyl)naphthalene-1,3-disulfonic acid as an antioxidant compound | Oct 30, 2023 | Issued |
Array
(
[id] => 19049402
[patent_doc_number] => 20240091371
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => BIO-ORTHOGONAL DRUG ACTIVATION
[patent_app_type] => utility
[patent_app_number] => 18/497645
[patent_app_country] => US
[patent_app_date] => 2023-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26211
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497645
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/497645 | BIO-ORTHOGONAL DRUG ACTIVATION | Oct 29, 2023 | Pending |
Array
(
[id] => 18970351
[patent_doc_number] => 20240050443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => Oral Formulation of Clonidine and Midazolam for Sedation in Dental Procedures
[patent_app_type] => utility
[patent_app_number] => 18/495845
[patent_app_country] => US
[patent_app_date] => 2023-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18495845
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/495845 | Oral formulation of clonidine and midazolam for sedation in dental procedures | Oct 26, 2023 | Issued |
Array
(
[id] => 19216241
[patent_doc_number] => 20240180945
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => COMPOUNDS AND PHARMACEUTICAL USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/493421
[patent_app_country] => US
[patent_app_date] => 2023-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43031
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18493421
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/493421 | COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Oct 23, 2023 | Pending |
Array
(
[id] => 19280048
[patent_doc_number] => 20240216521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 18/382896
[patent_app_country] => US
[patent_app_date] => 2023-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47718
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382896
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/382896 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | Oct 22, 2023 | Abandoned |
Array
(
[id] => 19034091
[patent_doc_number] => 20240083906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION
[patent_app_type] => utility
[patent_app_number] => 18/490596
[patent_app_country] => US
[patent_app_date] => 2023-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -61
[patent_words_short_claim] => 338
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18490596
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/490596 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | Oct 18, 2023 | Abandoned |
Array
(
[id] => 18953530
[patent_doc_number] => 20240041857
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AORTIC ANEURYSM
[patent_app_type] => utility
[patent_app_number] => 18/489303
[patent_app_country] => US
[patent_app_date] => 2023-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5788
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489303
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/489303 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AORTIC ANEURYSM | Oct 17, 2023 | Pending |
Array
(
[id] => 19172443
[patent_doc_number] => 20240158417
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/381121
[patent_app_country] => US
[patent_app_date] => 2023-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55406
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18381121
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/381121 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Oct 16, 2023 | Pending |